NC-BIOVENTUS
Bioventus , a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE , its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One® .1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ , to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis . 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage . 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol . 2019;37 Suppl 120(5):3-6.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marjan and RAK Hospitality Holding Announce Landmark Merger to Shape The Future Of Ras Al Khaimah As A Global Destination for Lifestyle and Investment22.10.2025 17:17:00 CEST | Press release
Marjan, the master developer of freehold properties in Ras Al Khaimah, and RAK Hospitality Holding, the government-owned investment and development arm in the Emirate, have announced a landmark strategic merger to create a unified entity operating under Marjan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022275206/en/ Marjan and RAK Hospitality Holding Announce Landmark Merger To Shape The Future Of Ras Al Khaimah As A Global Destination For Lifestyle And Investment (Photo: AETOSWire) This merger combines world-class hospitality expertise with visionary land development strategies to form a dynamic future-ready organization. Marjan will integrate real estate development, hospitality operations, and lifestyle experiences under one umbrella, positioning itself as one of the largest real estate developers in the UAE and the leading master developer in the Northern Emirates. Announcing the merger, His Highness Sheikh Ahmed
Venture Global Statement on CP2 Final Approval22.10.2025 16:33:00 CEST | Press release
The U.S. Department of Energy issued the final non-FTA export authorization for Venture Global’s CP2 facility in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “Venture Global is grateful for the Trump Administration’s final approval of CP2, a critical project that will supply American allies with low-cost LNG for decades, support thousands of jobs and greatly benefit the U.S. balance of trade. The CP2 project construction is well underway and we look forward to continue advancing the project safely and quickly to bring new LNG to the global market at a record pace beginning in 2027.” About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated bus
British Arab Commercial Bank Partners With Volante Technologies to Modernize Payments Infrastructure With PaaS22.10.2025 15:38:00 CEST | Press release
Volante’s cloud-native platform to unify BACB’s payment operations across SWIFT, CHAPS, Faster Payments, BACS, and more Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a new partnership with British Arab Commercial Bank (BACB), to modernize the bank’s payment processing infrastructure and replace legacy systems with a cloud-native platform. BACB will use Volante’s PaaS solution to automate and streamline the entirety of its payments volumes across multiple payment schemes, including SWIFT MT/ISO 20022, CHAPS, Faster Payments, BACS, and internal transfers. Volante’s solution enables BACB to move beyond legacy systems and manual processes, empowering the bank to raise straight-through processing rates and continue to provide a first-class service to its customers. BACB is an international wholesale bank, with $4.4 billion in assets, who provide a range of trade solutions to clients trading in and out of developing markets, across Africa and the Mi
Qualcomm Schedules Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call22.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its fourth quarter and fiscal 2025 on Wednesday, November 5, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its fourth quarter and fiscal 2025 results which will be broadcast live on November 5, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and internat
XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise22.10.2025 15:00:00 CEST | Press release
Collaboration ensures innovators benefit from critical resources to protect and advance breakthrough solutions XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators. For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom